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Abstract
Heterosexual exposure accounts for most HIV transmission in sub-Saharan Africa, and this mode, as a proportion of
new infections, is escalating globally. The scientific evidence accumulated over more than 20 years shows that
among the strategies advocated during this period for HIV prevention, male circumcision is one of, if not, the most
efficacious epidemiologically, as well as cost-wise. Despite this, and recommendation of the procedure by global
policy makers, national implementation has been slow. Additionally, some are not convinced of the protective
effect of male circumcision and there are also reports, unsupported by evidence, that non-sex-related drivers play a
major role in HIV transmission in sub-Saharan Africa. Here, we provide a critical evaluation of the state of the
current evidence for male circumcision in reducing HIV infection in light of established transmission drivers,
provide an update on programmes now in place in this region, and explain why policies based on established
scientific evidence should be prioritized. We conclude that the evidence supports the need to accelerate the
implementation of medical male circumcision programmes for HIV prevention in generalized heterosexual
epidemics, as well as in countering the growing heterosexual transmission in countries where HIV prevalence is
presently low.
Review
Implementation of male circumcision (MC) for HIV
prevention in sub-Saharan Africa remains disappoint-
ingly slow despite its proven efficacy of greater than
60% based on the results of three randomized controlled
trials (RCTs) conducted in the region [1-3]. These data
received support from a Cochrane review [4] and con-
firm more than two decades of data from observational
studies [5]. An as-treated meta-analysis for the 15 obser-
vational studies that adjusted for potential confounders
gave a summary risk ratio indicating a protective effect
of 65% that was identical to the initial findings from the
three RCTs [6,7]. Another meta-analysis of the RCT
data reported a relative risk reduction of 56% [8].
In a meta-analysis of 13 studies, 85% of which were
from sub-Saharan Africa, a 58% protective effect was
noted (53% for general populations and 69% for high-
risk populations) [9]. In this report, protection was 57%
for the RCTs and 61% for observational studies (cohort
studies 71% and case control 46%). In addition, if MC
status was ascertained by self-report, the protective
effect was 45%, but if by direct genital examination in
the clinic, it was 65%. These authors pointed out that
the current data on MC satisfy six of the nine criteria of
causality as outlined by Sir AB Hill, namely strength of
association, consistency, temporality, coherence, biologi-
cal plausibility and experiment [10].
With these definitive results, key international health
bodies [11,12] and numerous governments of countries
most affected [13,14] have formulated affirmative poli-
cies on MC for HIV prevention. There is now a consen-
sus among most experts in the HIV/AIDS scientific
community that MC, although not a “magic bullet”,i sa
critical component in the “tool box” of HIV prevention
approaches. Crucial to the effectiveness of MC policy is
an understanding of how effective MC will be in HIV
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any medium, provided the original work is properly cited.reduction, and as a corollary to this, the level of impor-
tance that heterosexual transmission plays in overall
HIV transmission in a population.
Historically, transmission of HIV has been attributed
to four main modes: sexual intercourse, transfusion, par-
enteral and perinatal acquisition [15]. In light of this,
multiple types of intervention strategies (behavioural,
structural and biomedical) have been advocated [16].
While scientists seek to provide the evidence base, pub-
lic policy makers must evaluate logically where the pre-
ponderance of evidence lies, and make correct decisions
based on a reasonable assessment of such evidence [17].
Urgent calls have been made by experts and advocates
to accelerate HIV prevention scale up in line with the
prevention principles [18,19]. However, in some
instances skepticism about the evidence has led to hesi-
tation, delays and inaction, leading to misery and, as in
South Africa, needless death for hundreds of thousands
from failure to expeditiously implement programmes
that work [20].
In the sub-Saharan African setting, the established
convention is that heterosexual transmission is the pri-
mary driver for the HIV epidemic. Recently, however,
some have argued that current HIV prevention interven-
tions are based on “insufficient information” on modes
of transmission and what works [21]. We agree that
there is a need to continually evaluate and update
knowledge on HIV transmission and what works in pre-
vention so as to better inform and reinforce policy mak-
ing and implementation. Therefore, in reinforcing the
policy imperative for MC as a proven method for pre-
vention of heterosexual HIV transmission, we first
review the state of knowledge on modes of HIV trans-
mission in sub-Saharan Africa. We then assess the
strength of current evidence for MC in protecting
against HIV infection, before analyzing current MC
implementation programmes in the region. Finally, we
highlight some of the outstanding issues and call for an
acceleration in MC implementation as an evidence-
based strategy to stem the HIV/AIDS epidemic.
What we know about the drivers of HIV infection
in sub-Saharan Africa
According to the latest Joint United Nations Programme
on HIV/AIDS (UNAIDS) epidemic update report, of the
33.3 million people living with HIV/AIDS worldwide at
the end of 2009, 92.5% were adults [22]. About half
were women and 67.6% live in sub-Saharan Africa,
where women comprise about 60% of cases [22]. Of
total infections globally, 2.5 million (approximately 7.5%
of the total) were in children (aged younger than 15
years), of whom 92% live in sub-Saharan Africa where
they comprise 10% of all cases [22]. Although some chil-
dren younger than 15 are sexually active, the prevalence
estimates show that 92.5% of cases globally and 90% in
sub-Saharan Africa are in the adult population [22].
While this in itself does not necessarily show associa-
tion with sexual activity, the preponderance of infection
in adults can only be explained by adult-specific factors
not affecting children. HIV distribution by sex and
across age groups are clearly consistent with sexual
behaviour as the main mode of transmission, as shown
by the significant and sudden increase in HIV in those
older than 15 years [22,23].
Consistent evidence for a major role of sexual inter-
course in transmission of HIV has been provided by
numerous modelling studies [24-28] and ecological
observations, published by the World Health Organiza-
tion (WHO) and UNAIDS in their annual report [22],
as well as in national estimates [29]. These data are col-
lected according to global norms [30,31] whose methods
are continually refined [32-35].
The effect of sexual transmission likely lie in context-
specific factors confounding host and agent alike. These
include stage of the disease, associated viral load, other
biological factors [24,36-40], as well as the socio-eco-
nomic and policy context [20,41]. Credible research
shows that the key initial drivers of the sexual transmis-
sion were a synergistic relationship between promiscu-
ous practices, coupled with individual-level biological
factors, namely sexually transmitted infections (STIs) (in
particular, genital ulcer disease, syphilis and HSV-2) and
lack of MC [40-44]. These factors also help explain the
differences in rate of spread across the continent [42,45].
Among these, the role of multiple and concurrent
partnerships (unstructured casual sex and polygyny) is
well documented in many sub-Saharan Africa countries
[46-51]. This is demonstrated, for example, in one of
the most detailed studies, involving 179 focus groups
and 116 in-depth interviews with diverse groups of peo-
ple (male/female, young/old, urban/rural) in typical day-
to-day settings in 10 countries of southern Africa that
have high generalized HIV epidemics [52]. Modelling
and network theory reveal dynamics of exposure [53,54].
Nevertheless, there is conflicting evidence on the extent
to which multiple and concurrent partnerships drives
the epidemic, as shown in recent assessments of the
existing literature by Lurie and Rosenthal [55] and
Sawers and Stillwaggon [56], as well as a debate hosted
on 27 October 2010 by the United States Agency for
International Development (USAID) and the World
Bank among opposing sides [57].
While heterosexual behaviour plays a leading role in
HIV transmission in sub-Saharan Africa, it is fair to ask
what proportion of infections is from non-sexual drivers.
These include: unsafe injections in medical and non-
medical settings [58,59], injecting drug use and blood
transfusion [60-62], mother to child transmission
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[65,66] and cultural practices [67,68], such as unsafe tra-
ditional MC and female genital cutting [69-72]. While
some argue that these play a significant role in sub-
Saharan Africa [21,68,73,74], such evidence is largely
circumstantial [62,75] and the level of such exposures
are altogether too low to fuel a generalized epidemic
[75-77]. One crucial illustration of this comes from a
modelling approach in use since 2003 [61], namely the
Modes of Transmission (MoT) approach. Developed by
the UNAIDS Reference Group to help country-level pol-
icy makers respond to the epidemic and prioritize inter-
ventions, the MoT approach provides a robust means
for estimating patterns of adult HIV transmission
through different routes [61].
To date, MoT analyses have been conducted in Kenya
[61], Lesotho [78], Swaziland [79], Uganda [80] and
Zambia [81]. They show that sexual behaviour accounts
for 94.1%, 97.0%, 94.0%, 99.6% and 99.8% of new infec-
tions, in each respective country, with the categories of
multiple partnerships and partners of multiple partner-
ships contributing more than half of all cases in Lesotho
and Zambia (Table 1). On the other hand, the popula-
tion of MSM in sub-Saharan Africa is not known, partly
due to laws prohibiting this behaviour in most countries,
although HIV prevalence in MSM is, however, high [65].
A systematic review estimated that the MSM route
makes an approximately 15.7% contribution to HIV pre-
valence in sub-Saharan Africa [82]. In one MSM cohort,
in Mombasa, Kenya, HIV prevalence was 43% in men
reporting exclusive MSM relations compared with 12%
in men reporting sex with both men and women [83].
In contrast, in Kenyan, Ugandan and Zambian studies,
infections arising from blood transfusion were insignifi-
cant (Table 1). Furthermore, a review of Demographic
and Health Surveys data from 10 countries indicated
that although having had a blood transfusion increases
risk of HIV infection among women (but not men) in
Cameroon and Uganda, blood transfusions are rare [62].
While non-sexual routes are relatively minor, they merit
continued monitoring [21,74,84]. Nonetheless, at pre-
sent, evidence-based means of reducing heterosexual
transmission should be prioritized [85]. One of these is
male circumcision.
Efficacy of male circumcision for HIV prevention:
an update on the evidence
As one of the oldest surgical procedures known to
humankind and the most widely practiced surgery
worldwide, male circumcision has served religious,
socio-cultural and health purposes [69,86-88]. Since the
suggestion in the 1980s that MC might prevent HIV
infection [89-91], numerous ecological, case-control and
cohort studies, reviews, systematic reviews and meta-
analyses have established that MC significantly reduces
the risk of heterosexual HIV infection [6-9,69,92-94].
The meta-analysis by Weiss et al of 27 observational
studies to the late 1990s showed a reduced risk in 21
studies [7]. In 15 studies that adjusted for confounding
factors, adjusted relative risk reduction was 0.42 (95%
CI 0.34-0.54) [7]. A Cochrane systematic review in 2005
assessing the quality of 37 studies of MC and HIV
noted that while the different methodologies showed
varying results, the protective effect of MC was sup-
ported consistently [93].
In 2005 and 2007, the efficacy of MC in HIV preven-
tion was verified beyond reasonable doubt by results
from three large RCTs, the gold standard of epidemiolo-
gical research, these being conducted in South Africa,
Kenya and Uganda [1-3]. Acceptance by the interna-
tional health community quickly followed [11-14]. In
2009, the Cochrane committee concluded that MC for
Table 1 Incident HIV infections by modes of transmission in five sub-Saharan Africa countries
% share of modes of HIV transmission in five countries
Uganda (2008) Kenya (2006) Zambia (2008) Swaziland (2008) Lesotho (2008)
Injecting drug users (IDUs) 0.28 4.84 0 1.1 0
Partners of IDU 0.01 0.2 0 0.1 0
Sex workers (SW) 0.91 1.25 0.75 3 0.47
SW clients 7.83 10.48 4.04 4.7 0.59
Partners of SW clients 1.81 1.1 1.81 2.6 1.68
Men who have sex with men (MSM) 0.61 4.49 0.99 3.6 2.89
Female partners of MSM 0.1 0.64 0.05 0.5 0.5
Multiple partnerships (MP) 23.73 18.31 33.96 13.4 31.04
Partners’ MP (PMP) 21.76 27.74 37.03 20.8 27.45
Mutually monogamous heterosexual sex 42.89 30.14 21.19 49.8 35.15
Medical injections 0.06 0.55 0.17 0.01 0.04
Blood transfusions 0 0.24 0.02 0.02 0
Bold text indicates sexual transmission [61,78-81].
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were required [4]. More recently, a systematic review of
37 late-phase RCTs of various HIV prevention interven-
t i o n sf o u n dM Ct oh a v eas t r o n g e re f f i c a c yi np r e v e n t -
ing HIV infection than vaccines, microbicides and
treatment of STIs [95]. An important development in
MC documentation has been the initiation by UNAIDS,
WHO and others of an online resource centre [96].
Research on acceptability of MC at the population
level in sub-Saharan Africa countries in 14 studies in
nine countries showed varied results, but was generally
high among men and women [97,98]. Continued assess-
ment of impacts, challenges and opportunities [99,100]
support the urgency of accelerating the implementation
of MC for HIV prevention [101,102]. In 2010, the US-
based Center for Global Health Policy called for “aggres-
sive scale up” of MC based on the evidence for its ability
to prevent HIV infection [103]. The quality of the evi-
dence supporting MC is “conclusive” [7], making MC a
sound recommendation for public health [104]. Such
evidence calls for skepticism to be dismissed [17].
Biological mechanism of male circumcision in
mediating HIV infection
Several suggestions have been made to explain the vul-
nerability of the foreskin to HIV infection. The inner
epithelium of the foreskin is mucosal, has been found to
lack protective keratin and to contain Langerhans cells
and T cells that express the HIV receptor, CD4
[87,105-109]. In an early study, HIV was taken up read-
ily by the inner, but not the outer foreskin epithelium in
explant culture [106]. Nearly a decade later, Ganor and
colleagues developed two new excellent models of the
foreskin epithelium: an improved explant model and a
3D immuno-competent in vitro model [108]. Their
human adult ex vivo foreskin explant model showed
that Langerhans cells and dermal T cells in the less-ker-
atinized inner foreskin have a significantly higher density
than in the outer foreskin. When the foreskin was
exposed to mononuclear cells highly infected with HIV,
but not free HIV, virions were found in the epidermis of
the inner foreskin within one hour, demonstrating that
Langerhans cells can efficiently transfer HIV to T cells
[108].
In another review, Ganor and Bomsel suggested that
the main pathway for HIV entry was driven by molecu-
lar signals, such as chemokines [109]. Findings of no dif-
ference [110] in, or greater [111], keratin thickness of
the outer versus the inner foreskin or in susceptibility to
HIV [112] have been dismissed as products of postmor-
tem changes and technical artifacts [109]. Foreskin
aspects relevant to HIV infection include the skin sur-
face area, the microbiologic environment, HIV-1-suscep-
tible cells and tissue structure, although more research
is needed to determine the relative contribution of each
[113].
Besides the ease of infection by inner epithelial cells to
HIV, HIV is suspected of infecting the body via tears in
the fragile inner surface of the foreskin and frenulum,
which are also susceptible to infection by other STIs
[43,87,105]. STIs hamper the ability of langerin in Lan-
gerhans cells to protect against HIV [107]. Thus the vul-
nerability of the foreskin to HIV infection lends
biological support to the extensive epidemiological evi-
dence for the protection MC confers against HIV infec-
tion in men during heterosexual intercourse.
The relationship between MC and HIV: evidence
and issues from population-based surveys
The highly acclaimed RCTs [1-3] would not have taken
place had there not been extensive observational evi-
dence in place already attesting to the ability of MC to
prevent HIV transmission. Nevertheless, RCTs have
been overvalued in medical studies and, by themselves,
they yield insufficient evidence for policy and must be
supplemented by observational evidence [5]. Population-
based surveys, in particular, the Demographic and
Health Survey (DHS) and the AIDS Indicator Survey,
have been cited frequently because of the insights they
provide into the patterning of HIV and MC in sub-
Saharan Africa [49,51,94,114,115].
Some have, however, disputed the association of HIV
prevalence and MC levels in such surveys. For example,
Gisselquist et al refer to DHS data showing higher pre-
valence of HIV in circumcised men in seven of 13 sub-
Saharan Africa countries [21]. In contrast, the ecological
analysis of 118 developing countries by Drain and col-
leagues showed that high MC prevalence was strongly
correlated with low HIV prevalence, independent of reli-
gion [94].
Furthermore, a recent cross-sectional analysis of DHS
data for 18 countries across sub-Saharan Africa from
2003 to 2008 involving 70,554 males aged 15 to 59 years
confirmed that being uncircumcised was significantly
associated with risk of HIV infection (OR 4.12; 95% CI:
3.85-4.42) and that risk increases with number of life-
time partners [115]. In light of the probable conflict in
interpretation, Wamai et al [116] have warned that DHS
data must be used with caution because of their widely
acknowledged inherent methodological problems, which
Gersovitz asserts need to be overcome in order to
improve reliability [117].
DHS data are, moreover, often bidirectional, indicating
contrasting and context-specific effects. In Tanzania, for
example, circumcision in men is higher in the upper
quintiles of education and wealth, and such men have
more sex partners [118]. So, not surprisingly, HIV pre-
valence in Tanzania, and numerous other countries
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higher education and income [119,120]. Furthermore,
this relationship is not necessarily linear and can change
over time [41]. The higher risky behaviour of such men,
such as being more likely to have concurrent partners
than uncircumcised men, would explain why, in certain
settings, they have a high HIV prevalence despite being
circumcised. This was pointed out in a recent analysis
of surveys in 21 countries in sub-Saharan Africa [49].
Since DHS data involve self-reported surveys, multiple
f a c t o r sh a v et ob ec o n s i d e r e dw h e ne x a m i n i n gt h er e l a -
tionship between MC and HIV prevalence. These
include risky sexual behaviour, time of MC, whether cir-
cumcision was complete, partial or performed at all,
marital status, education, wealth and patterns of resi-
dence (urban vs. rural). As an example, a study in
Uganda by Gray et al of a large cohort of HIV-negative
men found that MC significantly reduced HIV acquisi-
tion (unadjusted RR = 0.61; 95% CI = 0.37-0.97), but the
protective effect was lower for post-pubertal circumci-
sion (i.e., after 12 years of age); in Muslims, it was
further confounded by cultural and behavioural factors
[92]. In another example, a cross-sectional study in
Kenya, Lesotho and Tanzania found that while the pro-
tective effect of MC in adolescents was only “probable”,
in adults, the association of MC with lower HIV infec-
tion was unequivocal, indicating a protective effect in
males who were more likely to be sexually active [121].
There is a further point to note from ecological obser-
vation. Molecular clock analyses indicate that HIV has
existed for about 70 years and may have originated in or
near Cameroon (HIV-1), Guinea-Bissau (HIV-2) and the
Congo [122,123]. Yet none of these countries, where
most men are circumcised [69], have had adult preva-
lence rates as high as those observed in eastern and
southern Africa [22,39]. Hence, it could be reasonably
concluded that structural features of wealth and poverty
patterning behaviour [41], reported practice of multiple
and concurrent partnerships [49,52], couple discordancy
[124], prevalence of other STIs [40,42,44] and geo-
graphic variations in MC [69,94] have synergized to pro-
vide the “perfect storm” for the HIV epidemic in sub-
Saharan African countries with low MC prevalence
[43,91].
Male circumcision for HIV prevention: saving lives
and costs - the policy imperative
Unlike other HIV prevention strategies, MC is a one-
time procedure conferring potentially lifelong protective
benefits, so making it a highly cost-effective, life-saving
intervention, as revealed by several studies subsequent
to the RCTs [99,125-130]. For example, a study by the
UNAIDS/WHO/SACEMA Expert Group on Modeling
the Impact and Cost of Male Circumcision for HIV
Prevention found that one HIV infection would be
averted for every 15 circumcisions at a cost of US$150
to US$900 over a 10-year time horizon [130]. The popu-
lation-level impact of MC in reducing HIV incidence at
significant cost-savings is potentially enormous, as
shown in an early modelling study [104].
The Male Circumcision: Decision Makers’ Program
Planning Tool (DMPPT), developed recently by USAID’s
Health Policy Initiative in collaboration with UNAIDS,
has estimated the cost and impact of scaling up MC ser-
vices [131]. Using this model, an analysis of 14 priority
countries in eastern and southern Africa found that
scaling up MC services to cover 80% of all adult men
and newborn boys would, over the period 2009-2015,
avert more than 4 million new adult HIV infections at a
cost of US$2.5 billion [132]. This would yield total net
saving on cost of antiretroviral therapy (ART) of US
$20.2 billion over the same period [132].
In the DMPPT model, annual costs for implementa-
tion were projected to increase in the early scale-up
phase due to increased demand, peaking in 2012 and
declining thereafter, to level off at around $100 million
by 2015. Even countries with moderate HIV prevalence,
such as Rwanda, could reap significant savings in costs
relative to lifetime HIV treatment [133]. Furthermore,
the cost-effectiveness of MC, even in non- or low-gener-
alized HIV settings, increases when the procedure is
performed in newborns [134,135].
Despite being targeted at sexually active men, MC
provides important direct and indirect benefits to
women and children. For example, it was estimated that
in high-prevalence areas in Kenya and Zimbabwe, “cir-
cumcision confers a 46% reduction in the rate of male-
to-female HIV transmission”, with the effect of the
intervention “doubling the number of infections averted
among women” [136]. On the other hand, a RCT in
Uganda of sero-discordant couples in which the man
was HIV-positive was discontinued for futility after
21.7% of women in the intervention group and 13.4% in
the control group became infected [137]. This difference
was not, however, statistically significant, and many men
disobeyed instructions by resuming sexual intercourse
before healing was complete [137]. More recent findings
from a prospective multinational study in a similar sero-
discordant population showed “no increased risk and
potentially decreased risk” of infection due to MC to the
female partners [138].
Since women in sub-Saharan Africa show high accept-
ability of MC as part of comprehensive strategies for
HIV prevention, they can play an important role in the
adoption and implementation of MC by changing male
norms and in promoting infant MC [97,98,139]. By low-
ering infection in men and thence women, MC will
reduce overall infection rate and lower the number of
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moreover, simpler, more convenient, entails lower risk
and provides considerable savings in cost when com-
pared with circumcision at a later age, including the
cost of treatment over the lifetime for HIV-infected peo-
ple [132-135,140,141]. As an example, one study in the
USA indicated a 16% reduction in lifetime risk of HIV
infection in all males when circumcision is done in
infancy [134].
The cost savings from circumcision of boys early in
life is considerably greater than this because they enter
the sexually active period of their life with a reduced
risk of various STIs [87,142-146]. In the Ugandan RCT
of MC and HIV, MC was associated with a 25% reduc-
tion in prevalence in herpes simplex virus type 2 (HSV-
2), 35% lower human papillomavirus (HPV) [147] and
significantly reduced ulceration, trichomonas and bac-
terial vaginosis [148]. In the South African MC trial,
low-risk HPV prevalence was 8.5% in the intervention
arm compared with 15.8% in the control arm [149]. The
strong protective mechanism by which MC prevents
STIs in men likely involves both cellular and anatomical
factors [105,147].
That MC affords protection against HIV and multiple
STIs in heterosexual men and their female sexual part-
ners, and thereby their children, is not in doubt. On the
other hand, the effect of MC in preventing HIV in
MSM is less certain. In a South African study, HIV in
MSM was 80% lower if they were circumcised [150]. A
meta-analysis of studies from countries worldwide
showed 29% protection only for MSM who adopt pri-
marily the insertive role [151]. This was 73% in a
Cochrane analysis [152]. Not included was a recent
study of MSM in the high-prevalence setting of Andhra
Pradesh, India, where 18.6% of MSM were HIV positive
[153]. Although HIV was 70% lower in circumcised
receptive-only MSM, this was probably a result of
homophily. Further research in sub-Saharan Africa that
takes into account social and sexual networks in MSM
is needed [152,153].
With the current strong evidence that MC protects
against HIV and several common STIs, questions that
are important for policy consideration have arisen.
These include adverse effects, acceptability, risk com-
pensation, reduced efficacy due to early return to sex
after MC, disinhibition, long-term consequences and
external validity, as well as ethical issues. These have
been addressed in numerous publications
[11,12,87,97,98,116,154-156], none of which regard these
considerations as representing a basis for rejecting MC
as part of HIV prevention strategies. For example, the
arguments of external validity raised by Green et al
[157] ignore long-standing evidence from observational
studies [5] and have been strongly refuted as unfounded
[158]. In other examples, studies on disinhibition [159]
and risk compensation [155,160] showed no increase in
risky sexual behaviour [160] or early resumption of sex
[155].
Follow-up data of the Kenya RCT [2] indicated an
ongoing increase in the protective effect of MC against
HIV infections at 42 months [161] and 54 months
[162]. By five years, the protective effect reached 73% in
the Ugandan trial [163]. These results suggest that the
positive effect of MC will continue [158]. However,
implementation of national MC programmes triggered
by the RCT findings did not begin until 2008 [7], start-
ing in Kenya [164], and thus the long-term population
impact remains to be observed in those particular areas.
In light of that, it is imperative to continue monitoring
sexual behaviour after circumcision for continued
assessment of long-term positive impact.
Current state of practice in MC interventions in
sub-Saharan Africa
Following the recommendation by global health agencies
that MC be adopted as one of the critical tools for HIV
prevention in high-prevalence generalized heterosexual
epidemics [11,12], WHO and UNAIDS developed opera-
tional guidelines for scaling up MC services [165]. Pro-
grammatic development has, however, been slow, in
large part as a consequence of suboptimal funding.
In 2008, researchers argued that the international
community was not committing enough resources to
MC commensurate with the available evidence on what
works [166]. These authors noted that the 5% allocated
for MC, from an overall budget of $3.2 billion that
UNAIDS had estimated was needed to achieve universal
coverage for HIV programmes by 2010, fell far short of
the estimated need and demand for MC, especially
given its demonstrated efficacy relative to other inter-
ventions. Table 2 summarizes the current state of MC
intervention policy strategies, projected cost savings and
infections averted, as well as MC provision to date in
the 14 priority African countries. It can be seen that
programmatic development of MC to date is ongoing in
all countries, but differs markedly in extent [13,101,167].
Implementation in Kenya, the first country to com-
mence, was spearheaded by a national task force on MC
in 2008 [14]. Other countries have, or are in the process
of developing similar policies, implementation guidelines
and strategies. Some, like Kenya and Lesotho, have
developed formal MC policies, while others, such as
Botswana and Rwanda, have incorporated MC into
existing HIV prevention policies. Translating science
into policy is often challenging [168], and we acknowl-
edge that development of documents and programmes
through consultative and collaborative processes invol-
ving stakeholders in the health ministries, HIV/AIDS
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Country HIV
prevalence
(%)
Men
circum-
cised
(%)
Policy framework Implementation
strategy, plan
status
MC delivery structure Potential infections
averted by scaling
up MC to 80% by
2015 and maintain
rate through 2025*
Total
Net
Savings,
2009-
2025
(US$)
Circum-
cisions
to date
Estimated
number of
MCs needed
to reach
80% target
Achievement
towards 80%
target (%)
Botswana 17.6 11.2 MC as part of existing HIV
prevention policy
In place Services integrated in
existing HIV prevention
strategies
62,773 248
million
11,197 345,244 3.2
Phased scale-up
goal, 80% of 0-49
years HIV-negative
men by 2014
Ethiopia 1.4 -
National
93 -
National
MC as an additional HIV
prevention strategy. Regional MC
Task Force is to be established;
draft regional MC strategic
direction document under
finalization.
Under
development
MC to be provided in
100% of medical facilities
in Gambella (one hospital
and 25 health centres)
1,479 5.8
million
5,786 100,000 5.8
6.0 -
Gambella
46 -
Gambella
Target to provide
services in 100% of
healthcare facilities
in Gambella
Region
Kenya 7 - National 86-
National
MC policy in place: ‘National
Guidance’ for MC
In place Stand alone and
integrated, mobile clinics;
prison services
73,420 247
million
232,287 860,000 27
15.4 -
Nyanza
48 -
Nyanza
Target to reach
80% of 15-49 year
old men (1.1
million men) and
newborns by 2013
Lesotho 24 52 MC policy in place In place MC to be integrated in
HIV prevention services
focused in MNCH settings
106,427 618
million
4,000 376,795 1
Launched in 2010
Malawi 11 21 In place National
operational plan
includes voluntary
MC
Currently offered by free-
standing clinics. Scale-up
structure not yet
developed
240,685 1.2
billion
3,119 2,101,566 0.1
Mozambique 12 52 Formal policy developed MC included in
operational plan
for HIV prevention
MC services available on
demand; adolescent and
neonatal MC are planned.
215,861 1.5
billion
7,733 1,059,104 0.7
Rollout in pilot
sites
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7Table 2 Design and implementation of MC services for HIV prevention in 14 priority countries in east and southern Africa, 2011 (Continued)
Namibia 13 21 MC policy approved In place Stand-alone, mobile
services are being
considered. Plans to
integrate into hospital
services.
18,373 120
million
1,987 330,218 0.6
Rollout in pilot
sites
Rwanda 3 12 Formal policy in development.
Detailed operational plan in place
In place Formal scale up started in
the military. Plans to
integrate into standard
HIV prevention services.
56,840 200
million
1,694 1,746,052 0.1
Detailed
operational plan
being rolled out
South Africa 18 42 Draft policy in place, under
finalization
In place Facility based, and stand-
alone centres and camps,
scale up from Orange
Farm to 143 sites
1,083,869 6.5
billion
131,117 4,333,134 3.4
Currently being
scaled up
nationwide
Swaziland 26 8.2 Policy adopted by cabinet In place Formal scale-up of
integrated services
started; dedicated
“circumcision Saturdays’
56,810 332
million
18,869 183,450 13.3
Tanzania 5.7 67 Policy under way Under
development.
Plans to target 8
regions with high
HIV and low MC
prevalence
Scale-up demonstration
sites, MOVE strategy
recommended in the
public sector
202,900 966
million
18,026 1,373,271 1.4
Uganda 6.4 25 Policy in place In place Piloted in the military and
a mobile site, plans to
integrate into routine
services
339,524 2 billion 9,052 4,145,184 0.2
Zambia 14 12.8 Cabinet approved MC as part of
HIV prevention policy
In place Multi-sectored approach
focused on military,
police, prisons, and
neonatal services
339,632 2.4
billion
81,849 1,949,292 4.2
Target of 250,000
MCs a year; MC
sites to increase to
300 by 2014
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7Table 2 Design and implementation of MC services for HIV prevention in 14 priority countries in east and southern Africa, 2011 (Continued)
Zimbabwe 14 10 Policy in place Under
development
(2010-2014)
Services offered through
mobile and free-standing
sites and in public health
clinics. Nationwide
neonatal MC planned
565,751 3.8
billion
13,977 1,912,595 0.7
Notes and data sources: Ethiopia MC data (personal communication, Hannah Gibson, Country Director Jhpiego, Ethiopia) and estimated target [173]; Lesotho (4000 annual circumcisions before programme
intervention) [169]; for Zimbabwe 30,000 circumcisions have previously been reported [170]; all other data [13,132,167,171].
* The 80% target in all three columns is for uncircumcised males 14-49 years.
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7agencies, non-governmental organizations, academia and
donor partners, as was the case in Kenya, can be time
consuming.
It is nevertheless of concern that the numbers circum-
cised across the various countries three years after pol-
icy recommendations are very low relative to targets
(Table 2). The latest WHO/UNAIDS report indicates
cumulative circumcision figures up to 2010 since scale-
up started in 2008 at 555,202, i.e., 2.7% of the 20.8 mil-
lion target [167]. That 74% (410,904) of these occurred
in 2010 alone indicates that the momentum is rising,
but needs to accelerate still. As the DMPPT modelling
indicates, to achieve the projected outcomes, the 14
countries will need to reach 12 million circumcisions at
peak period in 2012 [132]. Accordingly, five countries
(Malawi, South Africa, Tanzania, Uganda and Zim-
babwe) would require at least one million circumcisions
each in 2012 [132].
In most of these countries, MC prevalence varies by
region and it is logical that, in the scale-up phase, pro-
grammes for MC deliberately target low MC localities,
such as is occurring in Ethiopia, Kenya and Namibia.
However, many of the current programmes are confined
to small or pilot settings. Data available for Lesotho are
pre-scale up [169]; for Zimbabwe, they are from several
clinical sites [167,170]; and for South Africa, they have
scaled-up from Orange Farm [171], where the RCT in
that country was conducted, to over 140 sites [167]. In
Gambella, Ethiopia, services are currently provided in
one hospital and seven health centres (personal commu-
nication, Hannah Gibson, Country Director Jhpiego,
Ethiopia).
With a growing demand for MC services and the
potential cost and life savings, it is imperative that scale
up be rapidly accelerated [103]. At the current rate of
service provision, 12 million MCs by 2012 across the 14
countries are highly unlikely to be met, so putting in
jeopardy many lives and failing to achieve the desired
cost savings.
In Kenya, just 232,200 MCs have been completed
[167], the largest number of any country. A speeded-
up rapid-results initiative intervention during a 30-day
period in 2009 conducted by 95 teams, each of four
persons, at a range of 9.6-22.8 circumcisions per team
per day, achieved 36,000 circumcisions (Robert Bailey,
personal communication). A similar intervention con-
ducted over five weeks during November-December
2010 achieved 51,000 circumcisions (Robert Bailey,
personal communication). At these rates, Kenya would
need several similar rapid-results initiatives to reach
the national goal of one million circumcisions by 2013
[172]. Nevertheless, Kenya’s programme is a model for
other African countries and, if adopted, could advance
the 2012 goal.
Many challenges stand in the way of implementing
MC programmes. These include cost, need for training
of health personnel, other health system barriers, the
politics surrounding policy development, funding and
changing socio-cultural perceptions and beliefs about
MC [13,94,101,164,166,172,173]. In Gambella, Ethiopia,
the regional hospital reportedly cannot meet even a
small demand of 10 circumcisions per week due to staff
shortages and lack of training [173].
Currently, the most informative assessment of MC
programmes comes from Kenya [164]. This report
reveals that of 81 government health facilities surveyed
in Nyanza (the target location of MC services), none
had the capacity to implement the full package of volun-
tary circumcision outlined in the national guidelines
[14]. Challenges included lack of a theatre, MC kits and
supplies, medical personnel to perform the procedure,
and data monitoring tools. Due to this, most of the
reported 230,000 circumcisions were done by partner
organizations largely in high-demand settings using
mobile teams [164]. The Kenya programme offers many
lessons for other countries.
Health provider training and service models being
developed will need to be tailored around specific exist-
ing health systems and services infrastructure, HIV epi-
demiological profiles and determinants, as well as MC
prevalence and demand. Reaching the estimated 100,000
men that need to be circumcised in Gambella, Ethiopia,
for example, will require a massive increase in trained
personnel to conduct the surgical procedure [173]. Since
MC programmes are targeting healthy men, high stan-
dards for surgical staff training and post-operative care
are essential. This includes strictly following established
national and international guidelines for sterile surgical
practice [11,12,14,144,165].
To increase the number of health personnel who can
perform safe circumcisions, novel service models should
be adopted. The rapid-results initiative pursued in
Kenya is based on intensive mobilization of resources
(human, equipment and financial) in high-demand set-
tings through community approaches [164]. Models for
Optimizing the Volume and Efficiency of MC Services
("MOVE”) is an additional approach for meeting
demand. Currently practiced in South Africa, it is
focused on increasing the efficiency of staff and time by
considering alternate surgical methods and modifying
facilities for efficient use [174]. Consideration should
also be given to promoting task shifting for nurses and
clinical officers as per WHO guidelines [175]. Already in
practice in Kenya [164] and Zambia [167], it is a com-
ponent of proposals in several other countries, such as
Namibia, Lesotho [13].
In some of the scale-up countries, traditional circum-
cisers, already used widely [72], can play a role in
Wamai et al. Journal of the International AIDS Society 2011, 14:49
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Page 10 of 17meeting demand [176], but only if they receive adequate
certification for acceptable standards of surgical MC. On
the other hand, as exemplified by the high (90%) prefer-
ence among men and women for medical MC in a tra-
ditionally circumcising community from northern
Tanzania, more efforts should be made to provide this
medical service in a culturally appropriate fashion, so
encouraging uptake [177].
Preliminary data are also becoming available on
devices that could facilitate quicker and safer adult cir-
cumcision [178]. These include the Shang Ring [179]
(which produced good results for safety and acceptabil-
ity in a field test in Kenya [180]), circumcision template
[181], the recently acclaimed PrePex system [182], and
the Tara KLamp [183], for which further assessment is
needed [178] after adverse effects were initially reported
[184]. In an important development, WHO has provided
a framework for clinical evaluation of devices for adult
MC [185], in addition to those already recommended
for infant MC [144].
Where do we go from here?
While welcoming continued debate about what drives
HIV in high-prevalence populations and what works in
HIV prevention programmes, we echo the call made by
experts and advocates four years ago [186] and more
recently [103], including a political declaration of the
United Nations [187], urging an acceleration in imple-
mentation of proven approaches, such as MC. There are
multiple reasons for reiterating this call. First, while the
incidence of HIV is now declining in many countries in
sub-Saharan Africa, nearly 70% of new HIV infections
globally remain in this region [22]. The rate of new
infections therefore needs to decelerate much faster
there if the crisis is to be stemmed. Towards that end,
policy makers, researchers and practitioners should
direct energy towards viable, practical and efficacious
solutions in an accelerated campaign.
Second, MC could stem epidemics of HIV elsewhere
than Africa. Based on current UNAIDS data, the main
mode of infection globally (heterosexual transmission) is
growing, as reflected in the increasing proportion of
new HIV infections reported in women, for example, to
35% in 2009 from 21% in 1990 in Asia [22]. Although in
the USA, UK, Russia, Canada, Australia and the Asian
region, major exposure categories are MSM and inject-
i n gd r u gu s e r s ,h i g h e ri n c i d e n tH I Vt r e n d si nw o m e n
and heterosexual contacts [22,188] should ring alarm
bells [143,156,189]. Such recent trends are likely to be
exacerbated by uneven and declining MC levels, espe-
cially in such countries as the USA and Australia, which
traditionally, until the mid-1970s and early 1980s, had
MC rates of more than 90% [190,191]. In Australia, it is
heartening that infant MC is again rising [156].
In such settings as the USA, MC services are particu-
larly crucial, especially in African-Americans [189], who
comprise a disproportionately high number of persons
living with HIV [192,193] and in whom perinatal infec-
tion per 100,000 infants is 12.3 compared with just 0.5
in white infants [194]. Furthermore, African-Americans
have the highest heterosexual HIV rates [195], but
national data show that they also have rates of MC
lower than whites [190]. Therefore, given the current
epidemiological trends, interventions need to focus on
established patterns of transmission for which the popu-
lation-level impact in reducing HIV infections will be
high now and in the future.
Third, current evidence from RCTs shows that in
comparison to a protective effect of 46% for prophylaxis
[196], 39% for microbicides [197] and 31.2% for a vac-
cine [198], at the moment, MC, with a 60% or higher
efficacy [4], is the most effective biomedical HIV pre-
vention strategy in heterosexual men. Furthermore, MC
will help reduce HIV in women [136] and children
[140,141,143], as well as help lower risks for STIs
[146-148] that exacerbate HIV risk [199,200].
As part of the internationally recognized priority inter-
ventions for stemming HIV [201], and given the current
state of implementation, massive catch-up strategies for
adult MC seem to be the better investment in the short
term. Importantly, mainstreaming of neonatal MC as
part of a long-term strategy is both logical and clearly
more cost effective [133,134,140,143,156], and will help
systematize MC practice and services provision in the
primary healthcare system for future generations.
Furthermore, the much-needed scale up in sub-Saharan
Africa will require significant additional funds, reorien-
tation of expenditure allocation, and better, more
rational use of the already existing largesse
[132,164,166].
Last, continued research that addresses other issues
concerning MC will be valuable, in addition to those
already underway in various countries [13]. In particular,
careful research is needed to:
1. Regularly update the impact of MC on the HIV epi-
demic in the targeted areas by monitoring behavioural
changes following MC.
2. Compare different surgical approaches, including
the use of different low-risk devices for adult MC to
further improve on this procedure, and the cost effec-
tiveness of service models, such as the rapid-results
initiative, task shifting and “MOVE” for accelerating
delivery.
3. Explore novel hypotheses relevant to prevention
messaging, for example, does MC make condom use
easier and/or more pleasurable?
4. Evaluate how to best integrate MC messages into
existing communications and prevention programmes.
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tional MC practices and norms so that these can be
incorporated into regular scale-up programmes without
increasing overall risk in order to speed up MC
programmes.
6. Examine the effect of MC scale up on the health
services and health system resources (human and infra-
structural), as well as integration of the practice in the
formal healthcare system.
7. Establish the definitive biologic mechanism by
which MC protects against HIV infection through the
penis.
8. Assess the role of MC as a potential platform for
promoting men’s health, including participation by
women in order to encourage couple sexual and repro-
ductive health.
9. Evaluate the integration of routine newborn MC in
maternal-child health programmes.
Conclusions
Public health campaigns aimed at stemming the spread
of HIV/AIDS should address all known transmission
routes as specific epidemiological, resources and contex-
tual factors demand. We support the continued promo-
tion of the use of all effective methods. The effect of
doing so will be cumulative. We realize that MC defini-
tively disrupts the major mode of HIV transmission in
sub-Saharan Africa. We also realize that historical, cul-
tural and political controversies surrounding MC [86,88]
may provoke passionate debates. However, as Collins
argues, it is imperative that values underpinning scienti-
fic thought form the centre of public policy interven-
tions [17].
Given the present body of evidence, and contingent on
certain pre-conditions (e.g., that MC is conducted by a
qualified practitioner, under acceptable conditions of
hygiene, in the absence of contra-indications), at this
point in time, it is clear that medical MC in infancy,
childhood or adulthood produces far greater good than
harm. We urge policy makers to more urgently facilitate
implementation of MC as a public health measure to
stem the growing heterosexual transmission of HIV
worldwide and, in sub-Saharan Africa, to more quickly
reduce future epidemics. Not only is MC highly effica-
cious against HIV acquisition, but it also confers multi-
ple other health benefits, thus making it quite rightly a
“surgical vaccine” for the 21
st century [1,87,103,116,154].
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